Penghambatan Ekspresi Gen dengan Antisense Oligonukleotida sebagai Upaya Pengobatan Penyakit
Due to the development of biomolecular science eg. overexpression genes, genes that cause diseases can be identfied, Based on this fact, researchers developed a therapeutic strategy by inhibiting the gene expression using oligonucleotide antisense. Therapy using oligonucleotide antisense was based on a natural process of gene expression. Specific artificial antisense will match complementary with DNA and mRNA. By this process the transcription will stop. The effort of therapy is relatively new but a few have been carried out in the clinical trial phase. Obstacles are encountered in reaching the target cell by the oligonucleotide antisense.
2. Trent RJ. Molecular medicine : an introductory text for students. London: Churchill Livingstone; 1993.
3. Voet D and Voet JG. Biochemistry. 2nd Ed. USA: John Wiley and Sons Inc; 1995. p.915-1011.
4. Stryer L. Biochemistry. 4th Ed. New York: Freeman and Company; 1995.p.875-910
5. Tan TMC. Antisense nucleic acids – a rational approach for drug design. AsPac J Mol Biol.
Biotechnol. 1994; 2 (3): 166–173.
6. Szymkowski DE: Developing antisenseoligonucleotides from the laboratory to clinical trials.
Drug Discovery Today. 1996; 1: 415 – 28.
7. Myers KJ, Dean NM: Sensible use of antisense: how to use oligonucleotides as research tools. Trends in Pharmacological Science. 2000; 21: 19-23.
8. Gewirtz AM, Stein Cy A, Glazer PM. Facilitating oligonucleotide delivery: helping antisense deliver on its promise. Proc Natl Acad Sci. 1996; 93: 3161 – 63.
9. Putnam DA. Antisense strategies and therapeutic applications. Am J Health Syst Pharm. 1996; 53 (2): 151–160.
10. Raha M, Wang G, Seidman MM, Glazer PM. Mutagenesis by third-strand-directed psoralen adducts in repair-deficient human cells: high frequency and altered spectrum in a xeroderma pigmentosium variant. Proc Natl Acad Sci. 1996; 93: 2941.
11. Maher LJ 3rd. Prospects for the theurapetic use of antisense oligonucleotides. Cancer Invest. 1996; 14:1, 66-82.
12. Baserga R, Denhardt DT. Antisense strategies.Annals of the New York Academy of Science. 1992; 660:27 -35
13. Svinarchuk F, Bertrand JR, Malvy C. A short purine oligonucleotide forms a highly stable triple helix with the promoter of the murine c-pim-1 proto-oncogene. Nucleic Acids Res. 1994; 22: 3742.
14. Maine IP, Kodadek T. Efficient unwinding of triplex DNA by a DNA helicase. Biochem Biophys Res Commun. 1994; 204: 1119.
15. Lacoste J, Francois JC, Helene C. Triple helix formation with purine-rich phosporothioate containing oligonucleotides covalently linked to an acridine derivative. Nucleic Acids Res. 1997; 25: 1991.
16. Nellen W, Lichtenstein C. What makes an mRNA ant sense-itive? Trends Biochem Sci. 1993; 18:419.
17. Woolf T, Melton D, Jennings C. Specificity of antisense oligonucleotides in vivo. Proc Natl Acad Sci. 1992; 89: 7305.
18. Kim U, Wang Y, Sanford T, Zeng Y, Nishikura K. Molecular cloning of cDNA for double stranded RNA adenosine deaminase, a candidate enzyme for nuclear RNA editing. Proc Natl Acad Sci. 1994; 91: 11457.
19. Pyle AM. Ribozymes: a distinct class of metalloenzymes. Science. 1993; 26: 709.
20. James HA, Gibson I. The theraupetic potential of ribozymes. Blood. 1998; 91:371.
21. Khan IM, Coulson JM. A novel method to stabilise antisense oligonucleotides againts exonuclease degradation. Nucleic Acids Res. 1993; 2: 2957.
22. Agrawal, S. Antisense oligonucleotides: towards clinical trials. Trends in Biotechnology. 1996; 14: 376-87.
23. Soomets U, Hallbrink M, Langel U. Antisense properties of peptide nucleic acids. Front Biosci. 1999; 4 D: 782–86.
Copyright @2017. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (http://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted non-commercial used, distribution and reproduction in any medium
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.